JP5111729B2 - 肝成長及び肝保護のための組成物と方法 - Google Patents

肝成長及び肝保護のための組成物と方法 Download PDF

Info

Publication number
JP5111729B2
JP5111729B2 JP2004510702A JP2004510702A JP5111729B2 JP 5111729 B2 JP5111729 B2 JP 5111729B2 JP 2004510702 A JP2004510702 A JP 2004510702A JP 2004510702 A JP2004510702 A JP 2004510702A JP 5111729 B2 JP5111729 B2 JP 5111729B2
Authority
JP
Japan
Prior art keywords
liver
vegf
flt
agent
kdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004510702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005534648A (ja
JP2005534648A5 (https=
Inventor
ナポレオン フェララ，
ケニス， ジェイ． ヒラン，
クーテー， ジェニファー ル
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2005534648A publication Critical patent/JP2005534648A/ja
Publication of JP2005534648A5 publication Critical patent/JP2005534648A5/ja
Application granted granted Critical
Publication of JP5111729B2 publication Critical patent/JP5111729B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004510702A 2002-06-05 2003-06-05 肝成長及び肝保護のための組成物と方法 Expired - Fee Related JP5111729B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38663702P 2002-06-05 2002-06-05
US60/386,637 2002-06-05
PCT/US2003/017591 WO2003103581A2 (en) 2002-06-05 2003-06-05 Compositions and methods for liver growth and liver protection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010038622A Division JP2010159266A (ja) 2002-06-05 2010-02-24 肝成長及び肝保護のための組成物と方法

Publications (3)

Publication Number Publication Date
JP2005534648A JP2005534648A (ja) 2005-11-17
JP2005534648A5 JP2005534648A5 (https=) 2006-07-20
JP5111729B2 true JP5111729B2 (ja) 2013-01-09

Family

ID=29736189

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004510702A Expired - Fee Related JP5111729B2 (ja) 2002-06-05 2003-06-05 肝成長及び肝保護のための組成物と方法
JP2010038622A Withdrawn JP2010159266A (ja) 2002-06-05 2010-02-24 肝成長及び肝保護のための組成物と方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010038622A Withdrawn JP2010159266A (ja) 2002-06-05 2010-02-24 肝成長及び肝保護のための組成物と方法

Country Status (7)

Country Link
US (2) US7700571B2 (https=)
EP (2) EP2430923A1 (https=)
JP (2) JP5111729B2 (https=)
AU (1) AU2003251397B2 (https=)
CA (1) CA2486270C (https=)
IL (2) IL165392A0 (https=)
WO (1) WO2003103581A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025047927A1 (ja) 2023-08-31 2025-03-06 ペプチドリーム株式会社 Ｖｅｇｆｒ－２アゴニスト活性を有するペプチド複合体

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266696A1 (en) 2000-06-02 2001-12-11 Bracco Research Usa Compounds for targeting endothelial cells
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
JP5111729B2 (ja) 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法
ATE548447T1 (de) * 2004-01-14 2012-03-15 Novahep Ab Menschlicher hepatische vorläuferzellen und verfahren zur verwendung davon
US8070703B2 (en) * 2004-03-10 2011-12-06 Vision Quest Industries Incorporated Electrically stimulating orthotic device and segmented liner
WO2006014678A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
EP2447281B1 (en) 2005-03-24 2015-12-16 ThromboGenics N.V. Novel anti-PLGF antibody
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
EP1904095B1 (en) 2005-06-30 2013-05-29 VIB, vzw Treatment of liver cirrhosis and its complications
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
AU2007230580A1 (en) * 2006-03-27 2007-10-04 Genentech, Inc. Methods for treating kidney disorders
US8685730B2 (en) * 2006-05-02 2014-04-01 Wisconsin Alumni Research Foundation Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
CN101250498B (zh) * 2008-04-07 2010-06-09 南通大学附属医院 用载肝细胞生长因子聚乳酸-o-羧甲基壳聚糖纳米粒子的肝细胞培养方法
CA2736929C (en) 2008-10-02 2019-02-26 Life Sciences Research Partners Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
ES2788300T3 (es) * 2010-11-09 2020-10-21 Univ Cornell Regeneración hepática
ES2424476T3 (es) * 2011-03-31 2013-10-02 Bioalliance Pharma Nanopartículas cargadas con fármaco antitumoral quimioterápico
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
KR102461927B1 (ko) * 2016-02-17 2022-10-31 차의과학대학교 산학협력단 이식용 줄기세포 및 이를 포함하는 혈관신생의 유도 또는 촉진을 위한 이식용 약학 조성물
CN114224893B (zh) * 2022-01-25 2023-06-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 喹唑啉衍生物在制备防治砷致肝损伤药物中的用途
CN116869986B (zh) * 2023-07-13 2025-12-02 南方医科大学 β-羟基丁酸在制备促进肝细胞增殖和肝脏再生产品方面的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US6107046A (en) 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
DE69628652T3 (de) * 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ES2265931T3 (es) 1999-04-16 2007-03-01 Genentech, Inc. Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos.
US6475796B1 (en) * 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
US20020164310A1 (en) * 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
US6659223B2 (en) * 2001-10-05 2003-12-09 Collins & Aikman Products Co. Sound attenuating material for use within vehicles and methods of making same
JP5111729B2 (ja) * 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025047927A1 (ja) 2023-08-31 2025-03-06 ペプチドリーム株式会社 Ｖｅｇｆｒ－２アゴニスト活性を有するペプチド複合体

Also Published As

Publication number Publication date
EP1531676B1 (en) 2015-07-22
JP2005534648A (ja) 2005-11-17
EP1531676A4 (en) 2009-06-17
EP2430923A1 (en) 2012-03-21
HK1076227A1 (en) 2006-01-13
AU2003251397B2 (en) 2009-10-01
WO2003103581A3 (en) 2004-04-15
CA2486270A1 (en) 2003-12-18
EP1531676A2 (en) 2005-05-25
US20070122394A1 (en) 2007-05-31
CA2486270C (en) 2015-07-28
WO2003103581A2 (en) 2003-12-18
US7700571B2 (en) 2010-04-20
AU2003251397A1 (en) 2003-12-22
US20040170613A1 (en) 2004-09-02
IL165392A (en) 2015-11-30
JP2010159266A (ja) 2010-07-22
US7709455B2 (en) 2010-05-04
IL165392A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
JP5111729B2 (ja) 肝成長及び肝保護のための組成物と方法
Mise et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor
O'Neill et al. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth
Giavazzi et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis
Maione et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models
ES2274549T3 (es) Compuestos para la inhibicion de la angiogenesis por terapia de genes .
Singh et al. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy
EP0969720B1 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
Da et al. Tumor lymphangiogenesis and lymphangiogenic growth factors
PT1978993T (pt) Composições e métodos para diagnóstico e tratamento do cancro com base em recetores fzd humanos
Wang et al. Options of therapeutics and novel delivery systems of drugs for the treatment of melanoma
Abshagen et al. Foxf1 siRNA delivery to hepatic stellate cells by DBTC lipoplex formulations ameliorates fibrosis in livers of bile duct ligated mice
CA2398310A1 (en) Methods for treating kidney disorders with pax2
Fujimura et al. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells
Shibata et al. In vivo electrogene transfer of interleukin‐12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas
Shan et al. Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival
Bardella et al. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo
HK1076227B (en) Compositions and methods for liver growth and liver protection
Ribatti From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials
KR20040004681A (ko) 혈관재생 요법
US20030124093A1 (en) Method for treating kidney disorders
RU2787841C2 (ru) Композиции и способы для ингибирования протеолитического пути аргинин/n-дегрона
Shah Stem Cell‐Mediated TRAIL Therapy for Highly Aggressive Brain Tumors
US20090264357A1 (en) NOVEL AGENT THAT INHIBITS ANGIOGENESIS AND METASTASIS TARGETING mTOR SIGNALING PATHWAY
Onn Molecular Events Surrounding the Angiogenic Switch of Lung Cance r

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100413

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120817

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121010

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151019

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5111729

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees